Hayfin is pleased to announce that it is serving as the co-lead investor through its Private Equity Solutions strategy, alongside funds managed by Morgan Stanley Private Equity Secondaries, in a €320 million Single-Asset Continuation Fund established by Impilo to support its continued ownership of Immedica.

Headquartered in Stockholm, Sweden, Immedica is a pharmaceutical company focused on the commericalization of specialty medicines for rare and orphan diseases.  Serving patients in more than 50 countries, Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Established in 2018 by Impilo and an experienced management team, Immedica has quickly emerged as a leader in the European rare disease space, with revenues of c. EUR 100m and annual growth of more than 50%.

This Continuation Fund transaction follows the recently announced completion of Impilo’s partial sale of Immedica to KKR, who together with Impilo will jointly oversee Immedica through this next phase of growth.

Mirja Lehmler-Brown, Managing Director and Co-Head of Private Equity Solutions at Hayfin commented: “We are excited to continue our partnership with Impilo in supporting Immedica during this pivotal time for the business. The Continuation Fund will aim to support the company with funding for its continued  growth journey, furthering its mission to deliver essential therapies to patients with significant unmet medical needs.”